Business news

    Neuren Pharmaceuticals (ASX:NEU) shares fall on alleged drug safety concerns, sales overestimation

    Article Image

    Neuren Pharmaceuticals' shares plunged 13% following a report by US short seller Culper Research, alleging misrepresentation of the safety profile of Rett syndrome drug Daybue by licensing partner Acadia.

    The report also challenged high sales estimates and suggested a sales peak in August 2023.

    Neuren has not yet commented on the matter but halted trading its shares on the ASX.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa